Brawn Biotech Ltd
Brawn Biotech Ltd (BRAWN) last reported results for the quarter ended Jun 2023, with sales of ₹0.12 crore and net profit of ₹-0.04 crore. The stock last traded at ₹24.5, a market capitalisation of ₹7.35 crore, on a P/E of 56.5. Over the past 52 weeks the stock has ranged between ₹17.7 and ₹24.7. Figures are as of 6 Oct 2026 and are not real time.
Brawn Biotech Ltd share price and key metrics
- Current price
- ₹24.5
- Market cap
- ₹7.35 cr
- Stock P/E
- 56.5
- ROE
- %
- ROCE
- %
- Dividend yield
- 0.00%
- 52w high / low
- 24.7/17.7
Metrics as of 6 Oct 2026. Not real time.
Track Brawn Biotech Ltd
Cruxal reads every Brawn Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Brawn Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- -7%
- 5 Years
- 4%
- 3 Years
- 4%
- 1 Year
- 9%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Brawn Biotech Ltd quarterly results
| ₹ crore | Jun 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|
| Sales | 0.12 | 0.12 | 0.12 |
| Expenses | 0.09 | 0.08 | 0.16 |
| Operating profit | 0.03 | 0.04 | -0.04 |
| OPM % | 25.00% | 33.33% | -33.33% |
| Other income | 0 | 0.23 | 0 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 0.03 | 0.27 | -0.04 |
| Tax % | 0.00% | 14.81% | 0.00% |
| Net profit | 0.02 | 0.23 | -0.04 |
| EPS (₹) | 0.07 | 0.77 | -0.13 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Brawn Biotech Ltd annual results
| ₹ crore | Mar 2023 |
|---|---|
| Sales | 0.48 |
| Operating profit | -0.01 |
| OPM % | -2.08% |
| Net profit | 0.19 |
| EPS (₹) | 0.63 |
TTM is the trailing twelve months to the most recent quarter.
Brawn Biotech Ltd shareholding pattern
Promoters held 52.94% at Jun 2026, down from 53.66% at Jun 2025. DIIs 0.35%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 53.64% | 53.64% | 53.66% | 53.66% | 53.66% | 53.39% | 52.94% | 52.94% |
| DIIs | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% |
| Public | 46.02% | 46.02% | 46.01% | 46.00% | 45.99% | 46.27% | 46.72% | 46.72% |
| No. of shareholders | 4,157 | 4,060 | 4,024 | 3,975 | 3,958 | 3,444 | 3,303 | 3,284 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Brawn Biotech Ltd corporate filings
- Disclosure under Regulation 30 of SEBI LODR Regulations, 2015Company Updatelow impact
- Scrutinizers Report attached along with voting results for 41st AGMAGM/EGMmedium impact
- Brawn Biotech Ltd. concludes 41st Annual General Meeting; all resolutions passedAGM/EGMlow impact
Cruxal's analysis: Brawn Biotech Ltd. has successfully concluded its 41st Annual General Meeting held on…
Read the full analysis - Brawn Biotech Ltd. Announces Successful Conclusion of 41st Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Brawn Biotech Ltd. has formally notified the BSE regarding the conclusion of its 41st…
Read the full analysis - Closure of Trading Window for quarter ended 30.09.2026Insider Trading / SASTlow impact
- Brawn Biotech Ltd dispatches shareholder communications per Regulation 36Company Updatelow impact
Cruxal's analysis: Brawn Biotech Ltd has issued an intimation regarding the dispatch of letters to…
Read the full analysis - Brawn Biotech Ltd. announces 41st Annual General Meeting to be held on 29th September 2026Company Updatelow impact
Cruxal's analysis: Brawn Biotech Ltd. has issued a formal intimation regarding its 41st Annual General…
Read the full analysis - Brawn Biotech Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Brawn Biotech Ltd has submitted its Annual Report for the financial year 2025-26 in…
Read the full analysis - Brawn Biotech Limited Announces 41st AGM and Proposes Managerial Remuneration ApprovalAGM/EGMlow impact
Cruxal's analysis: Brawn Biotech Limited has scheduled its 41st Annual General Meeting for September 29…
Read the full analysis - Brawn Biotech Ltd. Reports Q1 FY2027 Financial Results with Net Loss of 4.00 lakhCompany Updatehigh impact
Cruxal's analysis: Brawn Biotech Ltd. reported its unaudited financial results for the quarter ended 30 June…
Read the full analysis - Brawn Biotech Limited Reports Q1 FY2027 Financial Results and Announces Statutory Auditor AppointmentBoard Meetingmedium impact
Cruxal's analysis: Brawn Biotech Limited reported revenue from operations of 6.08 crore for the quarter…
Read the full analysis - Brawn Biotech Limited schedules Board Meeting for August 13, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Brawn Biotech Limited has formally intimated the BSE regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.